Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin Looks To Be First Out Of The Blocks On US Ingrezza, With Zydus Second

US Ingrezza Legal Battles Wrapped Up, With Earlier Teva, Sandoz Deals

Executive Summary

ANDA sponsors targeting Neurocrine Biosciences’ Ingrezza (valbenazine) blockbuster are in position to launch – albeit with a 14-year wait that validates the strength of the originator’s IP.

You may also be interested in...



Neurocrine’s Ingrezza Adds Huntington’s Indication, May Have Competitive Edge

The company’s VMAT2 inhibitor joins others in the drug class with a warning about suicidal ideation, but its once-daily dosing without titration may be an advantage in chorea associated with Huntington’s disease.

Coherus Delivers First US Rival To Neulasta OnPro, As Biosimilar Interest Peters Out

“Innovating cancer care for patients is a winning strategy,” Coherus said as it delivered on the first US biosimilar version of Amgen’s dominant pegfilgrastim formulation, using an on-body device to deliver the medication, months after a protracted FDA approval.

‘Not Just Growth In AG Xyrem’ Hikma Underlines Following Strong 2023

Hikma welcomed a strong and profitable 2023, driven by the nourishing effects of its authorized generic Xyrem product, which will fall back this year as the rate of royalties owed to the brand’s innovator climbs. But the company is optimistic it can continue growth in 2024, including through its $1.2bn Injectables division, which rushed in to fill supply gaps last year.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153130

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel